First Choice Of Vascular Access Research Articles

Risk factors for arteriovenous fistula dysfunction in hemodialysis patients: a retrospective study

Arteriovenous fistula (AVF) is the first choice of vascular access in hemodialysis (HD) patients. However, the correlations between patient factors and the arteriovenous fistula patency remain unclear. Therefore, our study investigates the risk factors associated with AVF dysfunction in HD patients. A total of 233 end-stage renal disease (ESDR) patients who met the study inclusion criteria in the Nephrology Department of Hunan Provincial People’s Hospital between December 2020 and June 2022 were included in this study. The baseline demographic, clinical and laboratory parameters were collected at the time of AVF creation and analyzed. Of the 233 ESRD patients, 146 (62.7%) were male and the mean age was 56.11 ± 12.14 (21–82) years. The patients were followed for a median time of 14 months. Kaplan–Meier analysis showed a 6-, 12- and 24-month post-placement survival of 87.1%, 82.8% and 80.7%, respectively. Univariate Cox regression analysis revealed weight (HR, 1.03; P = 0.03) as a predictor for the loss of vascular access functionality. In addition, multivariate Cox regression analysis further demonstrated that sex (HR, 3.41; P = 0.03), weight (HR 1.08; P < 0.01) and phosphorus level (HR: 3.03; P = 0.01) are independent risk factors for AVF dysfunction. AVF dysfunction is highly associated with several risk factors including weight, phosphorus level, and sex. Positive intervention strategies targeting these potential factors, such as weight loss or oral phosphate binders could improve the long-term success of AVF.

Effect of far-infrared therapy device on arteriovenous fistula maturation and lifespan in hemodialysis patients: a randomized controlled clinical trial.

Arteriovenous fistula (AVF) is the first choice of vascular access for hemodialysis treatment, and its surgical maturity rate is not high, and its postoperative complications (mostly stenosis) significantly shorten its life. At present, there are few studies on treatment methods to improve the maturity and survival of AVF. In this study, the effect of far infrared therapy (FIR) on the maturity and longevity of arteriovenous fistula in hemodialysis patients was discussed, and the protective mechanism of AVF induced by FIR therapy was explored, aiming at exploring a new treatment method. The hemodialysis patients admitted to the 900th Hospital of the Chinese Joint Logistics Support Force of the People's Liberation Army from January 2021 to April 2023 were randomly divided into control group and intervention group, with 40 cases in each group. Among them, the control group was coated with mucopolysaccharide polysulfonate cream; Intervention group: The patients were treated with mucopolysaccharide polysulfonate cream and far infrared radiation at the same time. After 3 months' intervention, the arteriovenous fistula (vein diameter, mature time of arteriovenous fistula, blood flow controlled by pump during dialysis, blood flow of brachial artery during dialysis and the occurrence of complications of internal fistula (oozing, occlusion and infection) and the pain score (numerical rating scale, NRS) of the two groups were compared, and the curative effects were compared. There was no significant difference in general data between the two groups (P > 0.05), which indicated that the study was comparable. After 3 months' intervention, the vein diameter, pump-controlled blood flow and brachial artery blood flow in the intervention group were significantly higher than those in the control group (P < 0.05). And the maturity time, NRS score and complication rate of arteriovenous fistula were significantly lower than those of the control group (P < 0.05). The primary patency rate of AVF in the intervention group was higher than that in the control group, and the overall patency rate between the two groups was statistically significant (P < 0.05). As a promising new treatment method, far infrared therapy can effectively promote the maturity of AVF, increase venous diameter, pump controlled blood flow during dialysis, brachial artery blood flow during dialysis, and prolong the service life of AVF.

#5657 FRAILTY AND VASCULAR ACCESS IN HEMODIALYSIS PATIENTS

Abstract Background and Aims Frailty is a geriatric syndrome characterized by increased vulnerability to stressors. The elderly become vulnerable and susceptible to adverse outcomes for their health and to functional restrictions. Previous guidelines suggested fistula creation as first choice for vascular access. Current guidelines suggest a more tailored approach to the patient's needs. Despite the high prevalence of frailty in hemodialysis patients, there is paucity of work investigating the relationship between frailty and vascular access failure. The aim of the study was the estimation of frailty with different scores and relationship with the choice of first vascular access, the current vascular access and vascular failures. Method 67 patients in hemodialysis participated to the study (observational cross-sectional study). Frailty was assessed with 6 different scores,Clinical Frailty Scale (CFS), Frailty Phenotype (FP), Edmonton Frailty Scale (EFS), Groningen Frailty Index GFI), Short Physical Performance Battery (SPPB), Prisma-7 and ankle-brachial index (ABI) and hand grip were also estimated. The current vascular access, the first vascular access, the vascular access failures and the mean duration of the vascular accesses were also recorded. Finally, the levels of the hemoglobin, serum albumin, C reactive protein, cholesterol were measured for all patients and the hemodialysis adequacy (URR, sp Kt/V) was calculated from the levels of urea before and after the hemodialysis session. Finally, the levels of the hemoglobin, albumin, C reactive protein, cholesterol were measured for all patients and the hemodialysis adequacy was calculated from the levels of urea before and after the hemodialysis session. Results The first vascular access of hemodialysis presents statistically significant relation between frail and robust patients that start hemodialysis with central venus catheter and AVF-AVG respectively. (SPPB- tunneled CVC 85, 7%, non tunneled CVC 46,2% ρ=0,032, Prisma-7- frail tunneled CVC 100%, non tunneled CVC 76,9% ρ=0,018, Groningen FI -frail tunneled CVC 100%, non tunneled CVC 65,7% ρ=0,011, Εdmonton FS -AVF-AVG not frail 64,7%, vulnerable 20,6% ρ=0,042) (Table 1-4). ABI presented a statistically significant relationship with the current vascular access. 68,18% of the patients with normal ABI have AVF-AVG and 60,87% of patients with abnormal ABI have tunneled CVC (p=0,022). In addition, the number of vascular accesses per patient, the mean duration of the accesses and the premature failures (3 months after creation) don't present statistically significant relation with frailty. Conclusion The frailty score could be used as a tool for the choice of vascular access in hemodialysis patients. Further studies, in a larger number of patients, are required to define a reliable and easy to use frailty tool, which is best suited to dialysis access selection.

Oxidative stress: An essential factor in the process of arteriovenous fistula failure.

For more than half a century, arteriovenous fistula (AVFs) has been recognized as a lifeline for patients requiring hemodialysis (HD). With its higher long-term patency rate and lower probability of complications, AVF is strongly recommended by guidelines in different areas as the first choice for vascular access for HD patients, and its proportion of application is gradually increasing. Despite technological improvements and advances in the standards of postoperative care, many deficiencies are still encountered in the use of AVF related to its high incidence of failure due to unsuccessful maturation to adequately support HD and the development of neointimal hyperplasia (NIH), which narrows the AVF lumen. AVF failure is linked to the activation and migration of vascular cells and the remodeling of the extracellular matrix, where complex interactions between cytokines, adhesion molecules, and inflammatory mediators lead to poor adaptive remodeling. Oxidative stress also plays a vital role in AVF failure, and a growing amount of data suggest a link between AVF failure and oxidative stress. In this review, we summarize the present understanding of the pathophysiology of AVF failure. Furthermore, we focus on the relation between oxidative stress and AVF dysfunction. Finally, we discuss potential therapies for addressing AVF failure based on targeting oxidative stress.

Stable incidence and survival of arteriovenous fistulas over 39 years: A long-term national cohort study.

The age and number of comorbidities in the hemodialysis population has increased over time. This may influence the construction and survival of the arteriovenous fistula (AVF). The present study explored the incidence and survival of AVFs over a period of 39 years. A retrospective cohort study was conducted based on Danish registries. Incident hemodialysis patients between 1977 and 2015 were included. The incidence of AVF and factors associated with the construction of an AVF were described. Risk factors for AVF survival and repair were explored by Kaplan Meier and Cox proportional hazard analysis. The total number of arteriovenous accesses (AVF and arteriovenous grafts) were 10,187 and there were 4201 central venous catheters (CVC). No significant difference in the proportion of AVFs during the 39 years was seen. Age and renal diagnosis did not influence the proportion of AVFs. Patients with CVCs were found to have a significantly higher prevalence of comorbidities (p < 0.01). AVF survival remained stable during the 39 years. The first constructed AVF had the best survival, 35% still functioning after 15 years. Factors such as brachiocephalic AVF, female sex, and diabetic nephropathy increased the risk of AVF failure (Odds Ratio (OR): 2.46, 95% Confidence Interval (CI) (2.29-2.65), 1.17 (1.10-1.25), and 1.21 (1.12-1.3)), respectively. Despite an older dialysis population, the proportion and survival of the AVF in the Danish dialysis population has not changed, probably because of increased awareness of AVF as the first choice of vascular access and improved surveillance, surgery, and repair.

Identification of Pathways and Key Genes in Venous Remodeling After Arteriovenous Fistula by Bioinformatics Analysis

The arteriovenous fistula (AVF) is the first choice for vascular access for hemodialysis of renal failure patients. Venous remodeling after exposure to high fistula flow is important for AVF to mature but the mechanism underlying remodeling is still unknown. The objective of this study is to identify the molecular mechanisms that contribute to venous remodeling after AVF. To screen and identify the differentially expressed genes (DEGs) that may involve venous remodeling after AVF, we used bioinformatics to download the public microarray data (GSE39488) from the Gene Expression Omnibus (GEO) and screen for DEGs. We then performed gene ontology (GO) function analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and gene set enrichment analysis (GSEA) for the functional annotation of DEGs. The protein-protein interaction (PPI) network was constructed and the hub genes were carried out. Finally, we harvested 12 normal vein samples and 12 AVF vein samples which were used to confirm the expressions of the hub genes by immunohistochemistry. A total of 45 DEGs were detected, including 32 upregulated and 13 downregulated DEGs. The biological process (BP) of the GO analysis were enriched in the extrinsic apoptotic signaling pathway, cGMP-mediated pathway signaling, and molting cycle. The KEGG pathway analysis showed that the upregulated DEGs were enriched in glycosaminoglycan biosynthesis and purine metabolism, while the downregulated DEGs were mainly enriched in pathways of glycosaminoglycan biosynthesis, antifolate resistance, and ABC transporters. The GSEA analysis result showed that the top three involved pathways were oxidative phosphorylation, TNFA signaling via NF-K B, and the inflammatory response. The PPI was constructed and the hub genes found through the method of DMNC showed that INHBA and NR4A2 might play an important role in venous remodeling after AVF. The integrated optical density (DOI) examined by immunohistochemistry staining showed that the expression of both INHBA and NR4A2 increased in AVF compared to the control group. Our research contributes to the understanding of the molecular mechanism of venous remodeling after exposure to high fistula flow, which may be useful in treating AVF failure.

High low-density lipoprotein cholesterol level is the independent risk factor of primary patency rate of arteriovenous fistula.

An arteriovenous fistula is the first choice of vascular access in dialysis patients. However, the correlations between patient factors and the arteriovenous fistula patency rate remain unclear. Therefore, we examined the effect of dialysis patient factors on arteriovenous fistula patency rate. This study included 101 patients who received maintenance dialysis and used arteriovenous fistula for vascular access at Atami Hospital, International University of Health and Welfare in July 2018. A retrospective review was performed from the time of arteriovenous fistula creation to July 2018, and the primary and secondary arteriovenous fistula patency rates were investigated. The patency rate was calculated using the Kaplan-Meier method, and risk factor analysis was performed using Cox proportional hazards regression analysis. The primary patency rate of arteriovenous fistula was 71.2% at one year and 43.0% at five years, and the secondary patency rate was 92.7% at one year and 79.8% at five years. In the multivariate analysis, high low-density lipoprotein cholesterol (LDL-C) level and a history of diabetes were considered significant risk factors (HR 1.023, p value <0.01 and HR 2.550, p value <0.01, respectively). A log rank test was conducted on the groups of patients with LDL <90 mg/dl and LDL ≥90 mg/dl, and the <90 mg/dl group resulted in a good primary patency rate (p value 0.0327). High LDL-C level was considered the independent risk factors of arteriovenous fistula primary patency rate.

Predictors of Arteriovenous Fistula Early Failure in End-Stage Renal Disease Patients: Real-World Data in Surabaya

Arteriovenous fistula (AVF) is the vascular access of choice in prevalent hemodialysis end-stage renal disease (ESRD) patients. However, there was a significant proportion of early AVF failure and its predictive factor was conflicting in several studies. We conducted a retrospective cohort study in 225 AVFs created in 159 patients. The purpose of this study was to identify the predictive factors of AVF early failure. The data variables included age at AVF creation, sex, history of diabetes, hypertension, cigarette smoking, AVF location and side, history of subclavian tunneled dialysis catheter and history of preoperative ultrasound mapping. This information was collected by interviewing the patient and by AVF scar inspection. AVF that was never coming into use was classified as an early failure. AVF creation in the wrist was significantly associated with a higher early failure rate (29.9%) compared with AVF creation at the elbow (4.4%) (p < 0.001). There was no significant association in terms of AVF early failure in terms of the other variables. We concluded that wrist AVF is significantly associated with early failure. However, this finding should not preclude the National Kidney Foundation’s recommendation of using wrist AVF for the first choice of vascular access to conserve more proximal access sites for future use.

A Long “Biotube” Vascular Graft for Hemodialysis Access: Evaluation in an Animal Model

Introduction - In patients receiving hemodialysis, autologous arteriovenous fistula (AVF) is first choice for vascular access. On the other hand, artificial vascular grafts are needed in an underlying disease or second surgery. However, they had any risk such as infectivity or low patency. In-body tissue architecture (iBTA) can prepare collagenous tubes, called Biotubes, by using a patient's body as a bioreactor. Previously, autologous Biotubes grown in patient’s subcutaneous pouches were successfully bypassed the venous stenosis region as the first-in-human study. In this study, long Biotubes were implanted as canine or goat AV hemodialysis access. Methods - Disk-like molds (1 in photos) having spiral cylinder were embedded in beagles or goats subcutaneously for 2 months. Biotubes with diameter of 4 or 5 mm and wall thickness of 1.5 mm were obtained after removing the mold harvested (2 in photos). The Biotubes were stored in an alcoholic solution at room temperature. Immediately before implantation Biotubes were immersed in a 0.6% glutaraldehyde solution for 2 min. AV shunts were prepared with allogenic Biotubes (straight shape, length 10 cm for beagles, U-shape, 50 cm for goats) between the carotid artery and jugular vein. Follow up was performed with Doppler echo and angiography. Results - Following placement of all Biotubes, continuous thrill was felt by palpation and Doppler echo showed turbulent blood flow. Angiography revealed that all three straight beagle Biotubes were patent for 6 months without any abnormal deformation in vascular shape (3 in photos). Percutaneous punctures and compression hemostasis within several minutes at every other day were possible after 1 month of implantation. All two U-shaped goat Biotubes were also patent up to 3 months until now even with the length of 50 cm (4 in photos). Conclusion - Long Biotubes successfully created an AV shunt that maintained steady blood flow, suggesting that Biotubes can have high potential clinical use as vascular access for hemodialysis.

Application of in-body tissue architecture-induced Biotube vascular grafts for vascular access: Proof of concept in a beagle dog model.

The first choice of vascular access for hemodialysis is an autogenous arteriovenous fistula, because prosthetic arteriovenous grafts have a high probability of failure. In this study, Biotubes, in-body tissue architecture-induced autologous collagenous tubes, were evaluated for their potential use as vascular access grafts. Three animal implantation models were developed using beagle dogs, and the in vivo performance of Biotubes was observed after implantation in the acute phase as a pilot study. Biotubes (internal diameter ca. 4.0 mm, length ca. 5.0 cm, and wall thickness ca. 0.7 mm) were prepared through subcutaneous embedding of specially designed molds in beagle dogs for 8 weeks. The Biotubes were then implanted between the common carotid artery and the jugular vein of beagles via three methods, including side-to-side (in) -end-to-end (out) as type 1 (n = 4), side-to-side (both) as type 2 (n = 4), and side-to-end (in) -end-to-side (out) as type 3 (n = 1 using a composite Biotube). Although two cases in type 1 and 2 resulted in Biotube deformation, all cases were patent for 4 weeks and maintained a continuous turbulent flow. At 4 weeks after implantation, percutaneous puncture could be performed repeatedly without aneurysm formation or hemorrhage. Within a short implantation period, with limited animal numbers, this proof-of-concept study showed that Biotubes may have a high potential for use in vascular access.

The effects of preoperative blood pressure on early failure rate of distal arteriovenous fistulas for hemodialysis access

The first choice of vascular access for hemodialysis in patients with end-stage renal disease is a distal radiocephalic arteriovenous fistula (AVF). Early failure rates for these AVFs vary from 10% to 53%. The effects of predialysis hypotension on failure of AVFs have been described in the literature. Weather lower blood pressures affect early AVF failure has not been extensively studied. We conducted this study to evaluate the effects of preoperative blood pressures on early AVF failure. Ours was a prospective observational study over a period of 2 years that included 224 patients who underwent distal radiocephalic AVF creation. Only those patients were included whose fistulas were made by surgeons with an experience of greater than five cases. The systolic, diastolic, and mean arterial pressures (MAPs) were recorded preoperatively. Early failure was defined as failure to achieve vascular access from the fistula within first 4 months of its creation. The overall early failure rate was 27.7%. Early failure was more common in females and diabetic patients. The systolic, diastolic, and MAPs were significantly lower in patients with early failure (P < 0.05). In a multivariable adjusted analysis, lower preoperative diastolic and MAPs were predictors for early failure of distal radiocephalic AVF. Our study shows that patients with early failure of AVFs have lower preoperative blood pressure. A larger study is required to substantiate our findings and define target preoperative blood pressure for AVF creation.

Clinical Utility of a New Predicting Score for Radiocephalic Arteriovenous Fistula Survival

Radiocephalic arteriovenous fistula (RC-AVF) is the recommended first choice for vascular access (VA). The CAVeA2T2 scoring system was recently published (ipsilateral central venous catheter access, age >73years, vein <2.2mm, lower limb angioplasty, and absent intraoperative thrill). The aim of the present study was to assess the clinical utility of the CAVeA2T2 scoring system for predicting RC-AVFs survival in our center and its subsequent application in VA management. In this single-center retrospective study, all RC-AVFs performed from January 2010 to July 2014 were included. The CAVeA2T2 was applied. Primary, assisted primary, and secondary patency rates were measured. Sixty RC-AVFs were analyzed. Mean age was 64.3±14.7years. Mean CAVeA2T2 score was 1.23±1.2. The median fistula secondary patency was 13.7±1.6months. Secondary patency was at 6weeks and at 6, 12, and 24months: 88.3%, 66.7%, 55%, and 31.7%, respectively. Increasing score (≥2) was associated with a decrease in primary (log-rank, χ2 = 16.7, dif= 1, P=0.0001) and secondary patency rate survival (log-rank, χ2 = 5.4, dif = 1, P=0.0001). In addition, stratification of the CAVeA2T2 score into 3 groups (scores 0-1, 2, and 3+) retained its significance for primary (log-rank, χ2 = 19.4, dif = 2, P=0.0001) and secondary patency rate survival (log-rank, χ2 = 5.5, dif = 2, P=0.046) at the end of the study. In the present study, the CAVeA2T2 scoring system has proved to be a useful, easy to apply tool that is highly predictive of RC-AVF survival. Based on our results, we should avoid perform RC-AVFs, in those patients with CAVeA2T2 score ≥2 and late nephrology referral. Prospective studies should be designed to establish the management of patients with a higher CAVeA2T2 score.

Efficacy and safety of ultrasound-guided internal jugular vein catheterization in low birth weight newborn

BackgroundCentral venous catheterization is not the first choice of vascular access in neonates. Success depends on the size of the vessel and the skill of the health professional performing the procedure. The internal jugular vein provides a predictable path for central venous cannulation, although it is more difficult to cannulate infants than adults and even more difficult in smaller newborns. MethodsWe conducted a prospective study in 100 newborns, in which a 4 Fr ultrasound-guided central venous catheter was placed in the right internal jugular vein (RIJV). The study population was low birth weight (LBW) newborns <2500g, very low birth weight (VLBW) newborns <1500g and extremely low birth weight (ELBW) newborns <1000g. ResultsThere were 53% female patients, mean gestational age was 31weeks, mean weight 1352g and the CVC was placed at a mean of 12days of extrauterine life. Birth weight distribution was 39% LBW; 33% VLBW and 28% ELBW. A mean of two (1–8) attempts were necessary with a procedure duration of 16.8 (10–40) minutes. Success of RIJV catheterization was 94%. One attempt was necessary in 50% and up to 5 attempts in 95.7%. Success by weight was VLBW, 97.2%; ELBW, 92.9%; LBW, 91.7%. A venous hematoma occurred in 5% of cases. ConclusionsUltrasound-guided RIJV cannulation with real-time visualization to gain access to the central venous circulation in low birth weight newborns is effective and safe.

Nitric Oxide Resistance Reduces Arteriovenous Fistula Maturation in Chronic Kidney Disease in Rats.

BackgroundAutologous arteriovenous (AV) fistulas are the first choice for vascular access but have a high risk of non-maturation due to insufficient vessel adaptation, a process dependent on nitric oxide (NO)-signaling. Chronic kidney disease (CKD) is associated with oxidative stress that can disturb NO-signaling. Here, we evaluated the influence of CKD on AV fistula maturation and NO-signaling.MethodsCKD was established in rats by a 5/6th nephrectomy and after 6 weeks, an AV fistula was created between the carotid artery and jugular vein, which was followed up at 3 weeks with ultrasound and flow assessments. Vessel wall histology was assessed afterwards and vasoreactivity of carotid arteries was studied in a wire myograph. The soluble guanylate cyclase (sGC) activator BAY 60–2770 was administered daily to CKD animals for 3 weeks to enhance fistula maturation.ResultsCKD animals showed lower flow rates, smaller fistula diameters and increased oxidative stress levels in the vessel wall. Endothelium-dependent relaxation was comparable but vasorelaxation after sodium nitroprusside was diminished in CKD vessels, indicating NO resistance of the NO-receptor sGC. This was confirmed by stimulation with BAY 60–2770 resulting in increased vasorelaxation in CKD vessels. Oral administration of BAY 60–2770 to CKD animals induced larger fistula diameters, however; flow was not significantly different from vehicle-treated CKD animals.ConclusionsCKD induces oxidative stress resulting in NO resistance that can hamper AV fistula maturation. sGC activators like BAY 60–2770 could offer therapeutic potential to increase AV fistula maturation.

Catéter transhepático: última opción de acceso vascular en mujer de 26 años

El acceso vascular (AV) es la base fundamental de todo tratamiento extracorpóreo de diálisis, su funcionamiento adecuado infl uye directamente en la calidad de vida del paciente y en su morbi-mortalidad. El AV vascular ideal debe permitir el abordaje seguro y continuado del sistema vascular, proporcionar fl ujos sufi cientes para alcanzar una dosis de diálisis adecuada y carecer de complicaciones. Según las guías SEN la primera opción de AV es la fístula arteriovenosa (FAV): nativa preferentemente, protésica, etc. Sin embargo, cuando estas posibilidades se agotan, se recurre a catéteres permanentes tunelizados.

Outcome and complications of permanent hemodialysis vascular access in Nigerians: A single centre experience

It is widely accepted that autogenous arteriovenous fistula (AVF) carries less morbidity and mortality compared to all other forms of vascular accesses in maintenance hemodialysis patients. There is paucity of data on vascular access from sub-Saharan Africa. The aim of this study was to assess the outcome and complications of permanent vascular access in our center. The study is a prospective, hospital-based, longitudinal study. All consecutive patients on maintenance hemodialysis in Aminu Kano Teaching Hospital who were referred to the surgical unit of for creation of permanent hemodialysis vascular access were included in the study. The patient's clinical and demographic data were documented. Data about vascular access types, outcomes, and complications were obtained over a 1-year period from the time of vascular access creation. One hundred and seventy four patients were operated upon between January 2008 and December 2010 with a mean age of 46.4 years (range 18-76 years) and a male to female ratio of 1.5:1. Brescio--Cimino fistula was performed in 110 (63.2%) patients, brachiocephalic (Kauffmann) fistula in 51(29.3%), and synthetic graft in 1 (0.6%) patients respectively. Ten patients (5.7%) had brachio-brachial transposition arteriovenous fistula and 2 patients (1.1%) had transposition graft using harvested long saphenous vein. One-year patency rate was 63.2%. Complications encountered include AVF failure in 47(27.3%), steal syndrome in 2(1.1%), distal venous insufficiency in 2(1.1%), and false aneurysm in 6(3.5%) patients. The outcome of permanent vascular access is favorable in our patient population with a one-year patency rate of 63.2%. The first choice of vascular access in our maintenance dialysis population should be AVF.

The Significance of Upper Arm Cephalic Vein Disease in Vascular Access Creation

A radiocephalic AV fistula at the wrist or snuffbox fistula is the usual first choice for vascular access because it is more comfortable for the patient, easier to needle and gives a longer length of available vein. It also leaves more options for future access. On the other hand, proximal AV fistulae at the cubital fossa may have a reduced rate of early thrombosis and have been advocated by some as a first choice in the elderly,1 whose life expectancy on dialysis is reduced. A variety of factors have been shown to influence the success rate of AV fistula creation, such as vessel diameter and distensibility, proximal arterial disease, gender, age, coexisting arterial disease and diabetes, but thrombosis and phlebitis in the draining vein remain major determinants of patency. Preoperative duplex scanning can detect such problems and help determine the optimum level for an AV fistula. Radiocephalic AV fistulae drain via the cephalic vein as far as the cubital fossa, at which point blood may continue its proximal flow via the cephalic vein, the basilic vein or into the brachial veins via the deep perforating vein. In some patients the forearm cephalic vein remains patent but one or more of these proximal veins is compromised, usually as a result of previous intravenous cannulation. The question then arises as towhether the patency of a distal AV fistula is reduced if one of these veins is thrombosed or stenosed. In this issue, Lee et al.2 reported their investigation into whether occlusion or stenosis of the upper arm cephalic vein influences the patency of radiocephalic AV fistulae when an alternative route of venous drainage exists. They used routine preoperative venography rather than duplex scanning and found that a compromised upper arm cephalic vein significantly

Vascular access today

The number of patients with chronic kidney disease requiring renal replacement therapy has increased worldwide. The most common replacement therapy is hemodialysis (HD). Vascular access (VA) has a key role for successful treatment. Despite the advances that have taken place in the field of the HD procedure, few things have changed with regards to VA in recent years. Arteriovenous fistula (AVF), polytetrafluoroethylene graft and the cuffed double lumen silicone catheter are the most common used for VA. In the long term, a number of complications may present and more than one VA is needed during the HD life. The most common complications for all of VA types are thrombosis, bleeding and infection, the most common cause of morbidity in these patients. It has been estimated that VA dysfunction is responsible for 20% of all hospitalizations. The annual cost of placing and looking after dialysis VA in the United States exceeds 1 billion dollars per year. A good functional access is also vital in order to deliver adequate HD therapy. It seems that the native AVF that Brescia and Cimino described in 1966 still remains the first choice for VA. The native forearm AVFs have the longest survival and require the fewest interventions. For this reason, the forearm AVF is the first choice, followed by the upper-arm AVF, the arteriovenous graft and the cuffed central venous catheter is the final choice. In conclusion, VA remains the most important issue for patients on HD and despite the technical improvements, a number of problems and complications have to be resolved.

The D&amp;T Report

The D&amp;T Report

La ética de las decisiones: catéter o fístula arteriovenosa interna

Given the clinical characteristics of incident and prevalent patients in current hemodialysis programs, the successful use of internal arteriovenous fistulas (IAVF) to provide permanent vascular access is increasingly difficult. This difficulty seems to be the cause of the increase in the number of permanent catheters detected in almost all periodic hemodialysis programs. Compliance with the recommendations of the various “guidelines” does not seem to be feasible, indicating the need not only to reconsider our final objectives but also the indications for this technique. Thus, at the present moment, IAVF are no longer the first choice of vascular access for extracorporeal therapy in some patients. Furthermore, the ethical dilemma no longer lies in the choice between a fistula or a catheter but rather in whether to give the choice of access to the patient and/or the patient's relatives, individually tailoring the distinct types of access, but without forgetting the obligation to improve our results both in terms of the choice of materials and in placement of devices, as well as in terms of the care and maintenance of vascular access devices. Time is showing us that catheters are the best – or only – vascular access option for an increasing number of patients, obliging us to significantly improve the results currently reported in most publications.